|
1
|
Eberhart CE, Coffey RJ, Radhika A,
Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of
cyclooxygenase 2 gene expression in human colorectal adenomas and
adenocarcinomas. Gastroenterology. 107:1183–1188. 1994.PubMed/NCBI
|
|
2
|
Soslow RA, Dannenberg AJ, Rush D, et al:
COX-2 is expressed in human pulmonary, colonic, and mammary tumors.
Cancer. 89:2637–2645. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kirschenbaum A, Liu X, Yao S and Levine
AC: The role of cyclooxygenase-2 in prostate cancer. Urology.
58:127–131. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ristimaki A, Sivula A, Lundin J, et al:
Prognostic significance of elevated cyclooxygenase-2 expression in
breast cancer. Cancer Res. 62:632–635. 2002.PubMed/NCBI
|
|
5
|
Denkert C, Winzer KJ, Muller BM, et al:
Elevated expression of cyclooxygenase-2 is a negative prognostic
factor for disease-free survival and overall survival in patients
with breast carcinoma. Cancer. 97:2978–2987. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
O’Connor JK, Avent J, Lee RJ, Fischbach J
and Gaffney DK: Cyclooxygenase-2 expression correlates with
diminished survival in invasive breast cancer treated with
mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys.
58:1034–1040. 2004.PubMed/NCBI
|
|
7
|
Spizzo G, Gastl G, Wolf D, et al:
Correlation of COX-2 and Ep-CAM overexpression in human invasive
breast cancer and its impact on survival. Br J Cancer. 88:574–578.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Surowiak P, Materna V, Matkowski R, et al:
Relationship between the expression of cyclooxygenase 2 and
MDR1/P-glycoprotein in invasive breast cancers and their prognostic
significance. Breast Cancer Res. 7:R862–R870. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Holmes MD, Chen WY, Schnitt SJ, et al:
COX-2 expression predicts worse breast cancer prognosis and does
not modify the association with aspirin. Breast Cancer Res Treat.
130:657–662. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tari AM, Simeone AM, Li YJ,
Gutierrez-Puente Y, Lai S and Symmans WF: Cyclooxygenase-2 protein
reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory
effects in breast cancer cells. Lab Invest. 85:1357–1367. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Costa C, Soares R, Reis-Filho J, Leitao D,
Amendoeira I and Schmitt F: Cyclo-oxygenase 2 expression is
associated with angiogenesis and lymph node metastasis in human
breast cancer. J Clin Pathol. 55:429–434. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ranger GS, Thomas V, Jewell A and Mokbel
K: Elevated cyclooxygenase-2 expression correlates with distant
metastases in breast cancer. Anticancer Res. 24:2349–2351.
2004.PubMed/NCBI
|
|
13
|
Simeone AM, Nieves-Alicea R, McMurtry VC,
Colella S, Krahe R and Tari AM: Cyclooxygenase-2 uses the protein
kinase C/interleukin-8/urokinase-type plasminogen activator pathway
to increase the invasiveness of breast cancer cells. Int J Oncol.
30:785–792. 2007.PubMed/NCBI
|
|
14
|
Prosperi JR, Mallery SR, Kigerl KA, Erfurt
AA and Robertson FM: Invasive and angiogenic phenotype of MCF-7
human breast tumor cells expressing human cyclooxygenase-2.
Prostaglandins Other Lipid Mediat. 73:249–264. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Singh B, Berry JA, Shoher A, Ramakrishnan
V and Lucci A: COX-2 overexpression increases motility and invasion
of breast cancer cells. Int J Oncol. 26:1393–1399. 2005.PubMed/NCBI
|
|
16
|
Connolly EM, Harmey JH, O’Grady T, et al:
Cyclo-oxygenase inhibition reduces tumour growth and metastasis in
an orthotopic model of breast cancer. Br J Cancer. 87:231–237.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kundu N and Fulton AM: Selective
cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic
disease in a murine model of breast cancer. Cancer Res.
62:2343–2346. 2002.PubMed/NCBI
|
|
18
|
Roche-Nagle G, Connolly EM, Eng M,
Bouchier-Hayes DJ and Harmey JH: Antimetastatic activity of a
cyclooxygenase-2 inhibitor. Br J Cancer. 91:359–365.
2004.PubMed/NCBI
|
|
19
|
Ogunwobi O, Mutungi G and Beales IL:
Leptin stimulates proliferation and inhibits apoptosis in Barrett’s
esophageal adenocarcinoma cells by cyclooxygenase-2-dependent,
prostaglandin-E2-mediated transactivation of the epidermal growth
factor receptor and c-Jun NH2-terminal kinase
activation. Endocrinology. 147:4505–4516. 2006.PubMed/NCBI
|
|
20
|
Leone V, di Palma A, Ricchi P, et al:
PGE2 inhibits apoptosis in human adenocarcinoma Caco-2
cell line through Ras-PI3K association and cAMP-dependent kinase A
activation. Am J Physiol Gastrointest Liver Physiol. 293:G673–G681.
2007.PubMed/NCBI
|
|
21
|
Repasky GA, Zhou Y, Morita S and Der CJ:
Ras-mediated intestinal epithelial cell transformation requires
cyclooxygenase-2-induced prostaglandin E2 signaling. Mol
Carcinog. 46:958–970. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Z, Lai GH and Sirica AE:
Celecoxib-induced apoptosis in rat cholangiocarcinoma cells
mediated by Akt inactivation and Bax translocation. Hepatology.
39:1028–1037. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McMurtry V, Simeone AM, Nieves-Alicea R
and Tari AM: Leptin utilizes Jun N-terminal kinases to stimulate
the invasion of MCF-7 breast cancer cells. Clin Exp Metastasis.
26:197–204. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gonzalez-Villasana V, Nieves-Alicea R,
McMurtry V, Gutierrez-Puente Y and Tari AM: Programmed cell death 4
inhibits leptin-induced breast cancer cell invasion. Oncol Rep.
27:861–866. 2012.PubMed/NCBI
|
|
25
|
Li Z, Xu X, Bai L, Chen W and Lin Y:
Epidermal growth factor receptor-mediated tissue transglutaminase
overexpression couples acquired tumor necrosis factor-related
apoptosis-inducing ligand resistance and migration through c-FLIP
and MMP-9 proteins in lung cancer cells. J Biol Chem.
286:21164–21172. 2011. View Article : Google Scholar
|
|
26
|
Nieves-Alicea R, Colburn NH, Simeone AM
and Tari AM: Programmed cell death 4 inhibits breast cancer cell
invasion by increasing tissue inhibitor of metalloproteinases-2
expression. Breast Cancer Res Treat. 114:203–209. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J, Kuiatse I, Lee AV, Pan J, Giuliano
A and Cui X: Sustained c-Jun-NH2-kinase activity
promotes epithelial-mesenchymal transition, invasion, and survival
of breast cancer cells by regulating extracellular signal-regulated
kinase activation. Mol Cancer Res. 8:266–277. 2010.
|
|
28
|
Davidson B, Konstantinovsky S, Kleinberg
L, et al: The mitogen-activated protein kinases (MAPK) p38 and JNK
are markers of tumor progression in breast carcinoma. Gynecol
Oncol. 102:453–461. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yeh YT, Hou MF, Chung YF, et al: Decreased
expression of phosphorylated JNK in breast infiltrating ductal
carcinoma is associated with a better overall survival. Int J
Cancer. 118:2678–2684. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Johnston SR, Lu B, Scott GK, et al:
Increased activator protein-1 DNA binding and c-Jun
NH2-terminal kinase activity in human breast tumors with
acquired tamoxifen resistance. Clin Cancer Res. 5:251–256.
1999.PubMed/NCBI
|
|
31
|
Schiff R, Reddy P, Ahotupa M, et al:
Oxidative stress and AP-1 activity in tamoxifen-resistant breast
tumors in vivo. J Natl Cancer Inst. 92:1926–1934. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Garcia-Becerra R, Santos N, Diaz L and
Camacho J: Mechanisms of resistance to endocrine therapy in breast
cancer: focus on signaling pathways, miRNAs and genetically based
resistance. Int J Mol Sci. 14:108–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sweeney EE, McDaniel RE, Maximov PY, Fan P
and Jordan VC: Models and mechanisms of acquired antihormone
resistance in breast cancer: significant clinical progress despite
limitations. Horm Mol Biol Clin Investig. 9:143–163.
2012.PubMed/NCBI
|
|
34
|
Bianco S and Gevry N: Endocrine resistance
in breast cancer: from cellular signaling pathways to epigenetic
mechanisms. Transcription. 3:165–170. 2012. View Article : Google Scholar : PubMed/NCBI
|
